Paraneoplastic syndrome
| Paraneoplastic syndrome | |
| DiseasesDB | 2064 |
|---|---|
| eMedicine | med/1747 |
| MeSH | D010257 |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
A paraneoplastic syndrome is a disease or symptom that is the consequence of the presence of cancer in the body, but is not due to the local presence of cancer cells. These phenomena are mediated by humoral factors (by hormones or cytokines) excreted by tumor cells or by an immune response against the tumor. Sometimes the symptoms of paraneoplastic syndromes show even before the diagnosis of a malignancy.
Classification
Paraneoplastic syndromes can be divided into 4 main categories:
- Mucocutaneous paraneoplastic syndromes [1]
- Dermatomyositis (25-50% of adult patients have an underlying malignancy)
- Leser-Trélat sign, a sudden onset of many pigmented skin lesions
- Acanthosis nigricans
- Necrolytic migratory erythema
- Sweet's syndrome
- Pyoderma gangrenosum
- Neurological paraneoplastic syndromes [2]
- Paraneoplastic cerebellar degeneration associated with lung, ovarian, breast, lymphatic, and other cancers
- Encephalomyelitis (inflammation of the brain and spinal cord)
- Limbic encephalitis
- Brainstem encephalitis
- Opsoclonus (involving eye movement)
- Encephalitis triggered by a teratoma[3]
- Polymyositis
- Lambert-Eaton myasthenic syndrome (LEMS) in small-cell lung cancer
- Hematological paraneoplastic syndromes [4]
- Granulocytosis (increased granulocytes) due to the production of G-CSF
- Endocrine metabolic syndromes[5]
- Hypercalcemia in breast cancer and lung cancer (typically squamous cell) due to the production of PTHrP (Parathyroid hormone-related protein)
- SIADH associated w/ lung and CNS malignancies, typically small cell.
- Ectopic ACTH secretion associated with small-cell lung cancer, carcinoid tumor, thymoma and other cancers
- Tumor induced osteomalacia
- Others that may not fit into any of the above categories include:
Neurological
A particularly devastating form of paraneoplastic syndromes is a group of disorders classified as paraneoplastic neurological disorders (PNDs).[6] These paraneoplastic disorders affect the brain and central nervous system and they are degenerative. Symptoms of paraneoplastic neurological disorders include ataxia (difficulty with walking and balance), dizziness, nystagmus (rapid uncontrolled eye movements), difficulty swallowing, loss of muscle tone, loss of fine motor coordination, slurred speech, memory loss, vision problems, sleep disturbances, dementia, seizures, sensory loss in the limbs.
The most common cancers associated with paraneoplastic neurological disorders are breast, ovarian and lung cancer, but many other cancers have been linked to PNDs as well.
Treatment options include:
- Therapies to eliminate the underlying cancer such as chemotherapy, radiation and surgery, and
- Therapies to reduce or slow neurological degeneration. Rapid diagnosis and treatment is critical for the patient to have the best chance of recovery. Since these disorders are relatively rare, few doctors have seen or treated PNDs. Therefore, it is important that PND patients consult with a specialist with experience in diagnosing and treating paraneoplastic neurological disorders.
Organizations
The International Paraneoplastic Association (IPA) is an organization dedicated to providing support and information to those affected by paraneoplastic neurological disorders.
References
- ↑ Cohen PR, Kurzrock R (1997). "Mucocutaneous paraneoplastic syndromes". Semin. Oncol. 24 (3): 334–59. PMID 9208889.
- ↑ Nervous+system+paraneoplastic+syndromes at the US National Library of Medicine Medical Subject Headings (MeSH)
- ↑ Dalmau J, Tüzün E, Wu HY; et al. (2007). "Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma". Ann. Neurol. 61 (1): 25–36. doi:10.1002/ana.21050. PMC 2430743. PMID 17262855. Unknown parameter
|month=ignored (help) - ↑ Staszewski H (1997). "Hematological paraneoplastic syndromes". Semin. Oncol. 24 (3): 329–33. PMID 9208888.
- ↑ Paraneoplastic+endocrine+syndromes at the US National Library of Medicine Medical Subject Headings (MeSH)
- ↑ Rees JH (2004). "Paraneoplastic syndromes: when to suspect, how to confirm, and how to manage". J. Neurol. Neurosurg. Psychiatr. 75 Suppl 2: ii43–50. PMID 15146039.
External links
- Neuroimmunology, The Medical School, Birmingham University - Paraneoplastic neurological autoantibodies, Birmingham UK
de:Paraneoplastisches Syndrom Template:WH Template:WikiDoc Sources